Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 December, 2018 19:22 IST
Glenmark Pharmaceuticals launches Nourkrin in Russia
Source: IRIS | 01 Nov, 2018, 10.14AM
Comments  |  Post Comment

Glenmark Pharmaceuticals, a research-led globally integrated pharmaceutical company, today announced the launch of Nourkrin in Russia. Nourkrin is a globallyrenowned, clinically-proven proteoglycan replacement formula, for addressing one of the key underlying causes of hair loss in males and females.

Nourkrin Woman and Nourkrin Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals (Q,N,C,F)* Ltd., under a licensing agreement with Denmarkheadquartered firm Pharma Medico ApS.

Glenmark had already launched Nourkrin® Woman in India in early 2018.

Nourkrin contains Marilex, a unique and proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth. Nourkrin is a proven formula based on more than 56 scientific studies and is recognized by leading regulatory agencies globally.

''We are very happy to launch Nourkrin for both women and men in Russia. It is a much awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia offering patients relief from different types of skin disorders for several decades and Nourkrin will be a great addition to this portfolio,'' said, Csaba Kantor, Senior Vice President & Head, Asia, Russia & CIS, Glenmark Pharmaceuticals.

According to a survey conducted by market research firm GfK in 2017, 18.7 million women and 14.1 million men in Russia experienced hair loss over the preceding 12 months.

Nourkrin Woman and Nourkrin Man, available as tablets, are an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The product will be available through retail pharmacy chains as well as online pharmacies.

Shares of the company declined Rs 4.95, or 0.8%, to trade at Rs 616.00. The total volume of shares traded was 8,023 at the BSE (10.07 a.m., Thursday).

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Commercial Engg & Body Builders Co bags order worth Rs 1.52 bn - 19-Dec-2018 10:51
Glenmark Pharma forays into dermatology segment in U.S - 19-Dec-2018 10:33
M&M to hike stake in associate company Sampo Rosenlew - 18-Dec-2018 10:37
Glenmark Pharma gets nod for Fluocinolone Acetonide oil - 18-Dec-2018 10:08
BGR Energy Systems bags order worth Rs 494 mn from Tamilnadu Transmission Corp - 18-Dec-2018 10:04
Lupin receives approval from USFDA for Clobazam tablets - 18-Dec-2018 10:01
Ahluwalia Contracts (India) secures new order worth RS 4.25 bn - 17-Dec-2018 15:31
Lupin receives tentative USFDA approval for Tadalafil tablets - 17-Dec-2018 14:49
Gayatri Projects bags new order worth Rs 4.93 bn - 17-Dec-2018 09:43
Zydus Cadila receives USFDA approvals for two drugs - 17-Dec-2018 09:39
Biocon's API manufacturing facility completes USFDA inspection - 17-Dec-2018 09:36
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer